Results 281 to 290 of about 14,184,553 (374)

ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks between cycles) or a cycle followed by every‐other‐week (Q2W) dosing.
Ali A. Habib, Kristl G. Claeys, Vera Bril, Yessar Hussain, Kelly Gwathmey, Gregory Sahagian, Elena Cortés‐Vicente, Edward Brauer, Deborah Gelinas, Anne Sumbul, Rosa H. Jimenez, Daniela Hristova, Delphine Masschaele, Renato Mantegazza, Andreas Meisel, Shahram Attarian, On behalf of the ADAPT NXT Study Group   +16 more
wiley   +1 more source

A PANoptosis‐Based Signature for Survival and Immune Predication in Glioblastoma Multiforme

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective PANoptosis is a concept of total cell death characterized by pyroptosis, apoptosis, and necroptosis. We aimed to explore the clinical significance of PANoptosis‐related genes (PARGs) in glioblastoma multiforme (GBM). Methods Expression profiles of GBM were downloaded from the XENA database as a training dataset to construct a ...
Jun Yang, Da Lin, Dongyuan Liu, Dongxu Zhang, Hao Wang   +4 more
wiley   +1 more source

Comparing Rituximab and Cyclophosphamide in Induction Therapy for Childhood‐Onset Anti‐Neutrophil Cytoplasmic Antibody‐Associated Vasculitis: An ARChiVe Registry Cohort Study

Arthritis Care &Research, Volume 77, Issue 4, Page 504-512, April 2025.
Objective Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are chronic life‐threatening vasculitides requiring substantial immunotherapy. Adult trials identified rituximab (RTX) as an alternative to cyclophosphamide (CYC) for remission induction of GPA and MPA.
Samuel J. Gagne, Vidya Sivaraman, Else S. Bosman, Brett Klamer, Kimberly A. Morishita, Adam Huber, Alvaro Orjuela, Barbara Eberhard, Charlotte Myrup, Dana Gerstbacher, Dirk Foell, Eslam Al‐Abadi, Flora McErlane, Kathryn Cook, Linda Wagner‐Weiner, Melissa Elder, L. Nandini Moorthy, Paul Dancey, Rae Yeung, Raju Khubchandani, Samundeeswari Deepak, Sirirat Charuvanij, Stacey Tarvin, Susan Shenoi, Tamara Tanner, Kelly Brown, David A. Cabral, for the ARChiVe Investigators Network within the PedVas Initiative   +27 more
wiley   +1 more source

Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open‐Label, Phase 1 Trial

Arthritis Care &Research, Volume 77, Issue 5, Page 584-593, May 2025.
Objective This work aimed to evaluate the pharmacokinetics, efficacy, and safety of upadacitinib, an oral selective JAK inhibitor, in pediatric patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods In an open‐label, phase 1 study (SELECT‐YOUTH), enrolled patients, aged 2 to <18 years with pcJIA, received body weight–based ...
Hermine I. Brunner, Anna Shmagel, Gerd Horneff, Ivan Foeldvari, Jordi Antón, Athimalaipet V. Ramanan, Yuli Qian, Kristina Unnebrink, Shuai Hao, Heidi S. Camp, Nasser Khan, Wei Liu, Mohamed‐Eslam F. Mohamed   +12 more
wiley   +1 more source

Incidence of Side Effects Associated With Acetaminophen in People Aged 65 Years or More: A Prospective Cohort Study Using Data From the Clinical Practice Research Datalink

Arthritis Care &Research, Volume 77, Issue 5, Page 666-675, May 2025.
Objective The main objective of this study is to examine the safety of oral acetaminophen at its therapeutic dose in adults aged ≥65 years. Methods This population‐based cohort study used the Clinical Practice Research Datalink‐Gold data. Participants were aged ≥65 years registered with a UK general practice for at least 12 months between 1998 and 2018.
Jaspreet Kaur, Georgina Nakafero, Abhishek Abhishek, Christian Mallen, Michael Doherty, Weiya Zhang   +5 more
wiley   +1 more source

Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level.

, 1985
K.H. Örstavik, Per Magnus, H Reisner, K. Berg, J. Graham, W. E. Nance   +5 more
openalex   +1 more source

Association of Changes in Hand Pain With BMI, Employment, and Mental Well‐Being Over Four Years in Patients With Hand Osteoarthritis

Arthritis Care &Research, Volume 77, Issue 5, Page 614-622, May 2025.
Objective We aimed to characterize patients with hand osteoarthritis (OA) with deteriorating or improving hand pain and to investigate patients achieving good clinical outcome after four years. Methods We used four‐year annual Australian/Canadian Hand Osteoarthritis Index (AUSCAN) pain subscale (range 0–20) measurements from the Hand OSTeoArthritis in ...
Coen van der Meulen, Lotte A. van de Stadt, Saskia J. Buck, Frits R. Rosendaal, Sietse E. S. Terpstra, Margreet Kloppenburg   +5 more
wiley   +1 more source

PSY12 Factor Consumption for Prophylaxis and Treatment of Bleeding: Recombinant Factor Ix Fc Fusion Protein Compared With Conventional Recombinant Factor Ix [PDF]

Iorio, A, Karner, P, Krishnan, S, Lethagen, S, McCormick, N, Myrén, K   +5 more
core   +1 more source

Studies on Oral Administration of Concentrated Factor IX Preparation

, 1982
Masaharu Ueno, Isamu Horikoshi, Kaoru Takahashi, N Sakuragawa   +3 more
openalex   +2 more sources

Pregnancy Outcomes of Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Among Patients With Autoimmune Diseases: A Scoping Review

Arthritis Care &Research, EarlyView.
Objective Targeted synthetic disease‐modifying antirheumatic drugs (tsDMARDs) have expanded the management of autoimmune diseases, including rheumatic diseases. As the use of these drugs grows, it is important to understand their effects on pregnancy.
Vienna Cheng, Neda Amiri, Vicki Cheng, Ursula Ellis, Jacquelyn J. Cragg, Mark Harrison, Laurie Proulx, Mary A. De Vera   +7 more
wiley   +1 more source